Select a State

Global health R&D delivers for Oregon

US government investment in global health R&D has delivered

$98.4 million
to Oregon research institutions
1,300+ new jobs
for Oregon

Neglected diseases in Oregon

Chikungunya cases
8
Dengue cases
14
HIV diagnoses
2,196
Malaria cases
103
Tuberculosis cases
682
West Nile cases
67
Zika cases
52

Oregon's top USG-funded global health R&D institutions

Oregon Health and Science University
$84.7 million
Portland State University
$7.1 million
Oregon State University
$6.2 million
University of Oregon
$289 thousand

Oregon industry in global health R&D

DesignMedix
Location(s):
Portland
Hemax Health
Location(s):
Portland
mAbDx
Location(s):
Eugene
Najit Technologies
Location(s):
Beaverton
Sedia Biosciences Corporation
Location(s):
Portland
SIGA Technologies
Location(s):
Corvallis
Vir Pharmaceuticals:
Location(s):
Portland
Viti
Location(s):
Portland

Oregon's top areas of global health R&D by USG funding

40.1%
HIV/AIDS
10.0%
Malaria
23.5%
Tuberculosis
3.7%
Diarrheal diseases
2.6%
Salmonella infections
19.3%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
1.0%
Other
Non-allocable

Global health R&D at work in Oregon

Portland State University (PSU) researchers have revived a once-potent malaria drug and created a company to move it forward. For many years, chloroquine was considered a miracle drug in treating malaria until the disease developed resistance. Rather than abandon it, PSU scientists reversed the resistance process with chemicals. This work led to a group of chloroquine hybrids and the birth of DesignMedix, a Portland start-up specializing in new approaches to fight infectious diseases. With funding from investors, the company provides opportunities for students and jobs for the region, highlighting the economic benefits of global health R&D.

Footnotes